Dragontropin 20IU

DRAGONTROPIN 20IU is a high-concentration recombinant research reagent utilized primarily to investigate the complex signaling pathways of human growth hormone (HGH) and the secondary regulation of insulin-like growth factor 1 (IGF-1). As a potent agonist for the growth hormone receptor (GHR), it serves as a critical tool for exploring protein synthesis, cellular proliferation, and metabolic substrate partitioning. Dragon Pharma provides DRAGONTROPIN 20IU (Somatropin) at a purity level of 99%+, specifically for use in in-vitro laboratory experiments and preclinical investigative models.

Overview

In the fields of endocrinology and molecular biology, DRAGONTROPIN is a primary instrument for researchers exploring the somatotropic axis. This compound is a 191-amino acid polypeptide, synthesized to be biochemically identical to endogenous human pituitary growth hormone. The 20IU concentration allows for the study of dose-dependent cellular responses and the mapping of high-affinity receptor saturation kinetics. Dragon Pharma provides DRAGONTROPIN 20IU at a minimum purity of 99%, ensuring that researchers have access to a high-grade Research Compound capable of producing reproducible and accurate data in complex biological systems.

As scientific inquiry into age-related metabolic decline, musculoskeletal regeneration, and tissue engineering expands, the need for high-stability GH analogs has grown. This expanded profile examines the biochemical characteristics, structural integrity, and multifaceted research applications of DRAGONTROPIN 20IU.

Molecular Characteristics and Chemical Profile

The structural integrity of Dragontropin is essential for its ability to induce growth hormone receptor dimerization, which triggers the intracellular JAK/STAT signaling cascade.

• Chemical Identity: Recombinant Human Growth Hormone (Somatropin)
• Molecular Formula: C990H1529N263O299S7
• Molecular Weight: 22,125 Da (approx. 22.1 kDa)
• Purity: >99% (HPLC and SEC-HPLC verified)
• Form: Lyophilized powder
• Manufacturer: Dragon Pharma

Research Applications

The compound is utilized in various scientific investigative domains, including:

• Somatotropic Axis Mapping: Investigating the feedback loops between the hypothalamus, pituitary, and hepatic IGF-1 production.
• Anabolic Signaling: Mapping the activation of the mTOR and PI3K/Akt pathways in skeletal muscle cells.
• Adipocyte Metabolism: Studying the hormone-sensitive lipase (HSL) activation and its role in lipid mobilization.
• Tissue Regeneration: Assessing the impact of GH on collagen synthesis in tendons and ligaments.
• Cellular Senescence: Evaluating the influence of growth hormone levels on biological aging markers and DNA repair mechanisms.

Pathway and Mechanistic Context

The core value of DRAGONTROPIN 20IU in a laboratory setting is its ability to manipulate the JAK2/STAT5 Signaling Pathway.

Upon binding to the extracellular domain of the GHR, Dragontropin initiates a cascade that leads to the translocation of STAT proteins to the nucleus, where they regulate the transcription of genes responsible for growth and metabolism.

Key Mechanistic Shifts:

• Nitrogen Retention Enhancement: Dragontropin facilitates a positive nitrogen balance in cellular models, a key metric for studying anabolic states.
• Glucose Regulation Research: It is used to observe the "diabetogenic" effect of GH, investigating how high concentrations affect insulin receptor sensitivity.
• IGF-1 Induction: Researchers utilize Dragontropin to study the paracrine and endocrine effects of IGF-1 on bone and soft tissue development.

Primary Research Applications

1. Growth Hormone Deficiency (GHD) and Developmental Biology

Dragontropin is vital for studies involving pediatric and adult growth hormone deficiencies. Statistics indicate that Growth Hormone Deficiency affects approximately 1 in 3,000 to 1 in 10,000 people globally. Research into growth patterns shows significant demographic variation; for example, data indicates that the average height for African American men is 175.5 cm and 162.3 cm for women, compared to 177 cm for Caucasian men and 163.3 cm for Caucasian women. DRAGONTROPIN 20IU provides a high-concentration framework for investigating the physiological triggers that define these developmental trajectories.

2. Musculoskeletal Repair and Sarcopenia

Investigators use this compound to study the reversal of muscle wasting (cachexia) and the aging-related decline of muscle mass (sarcopenia). Research models focus on how somatotropic stimulation can preserve lean tissue during periods of high oxidative stress.

3. Metabolic Syndrome and Visceral Fat Research

In metabolic studies, Dragontropin is utilized to observe changes in body composition. Research indicates that GH stimulation can lead to a significant reduction in visceral adipose tissue (VAT), providing a model for treating obesity-related metabolic dysfunction.

Form and Analytical Testing

At Dragon Pharma, scientific accuracy is maintained through a rigorous manufacturing process using advanced recombinant DNA technology.

• Stability and Purity: The compound is lyophilized to preserve its delicate tertiary protein structure and prevent the formation of aggregates.
• Rigorous Analytical Verification: Every batch undergoes Size-Exclusion Chromatography (SEC-HPLC) and Mass Spectrometry (MS) to confirm the 191-amino acid sequence and ensure zero presence of bacterial endotoxins or truncated proteins.